Marlène Murris
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marlène Murris has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- James Duncan Chalmers
University of Dundee, Ninewells Hospital and Medical School, Dundee, UK
2 shared publications - Pierre-Régis Burgel
Department of Respiratory Medicine, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France
2 shared publications Adrien Tissot
INSERM, Service de Pneumologie, Center for Research in Transplant and Translational Immunology, UMR 1064, l'institut du thorax, Nantes Université, CHU Nantes, Nantes, France
1 shared publication- Alan Brown
Department of Biological Chemistry and Molecular Pharmacology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA
1 shared publication - Alan J. Quigley
Department of Radiology, Royal Hospital for Children and Young People, Edinburgh, UK
1 shared publication - Alex von Kriegsheim
Cancer Research UK Edinburgh Centre, Institute of Genetics and Cancer, University of Edinburgh
1 shared publication
Latest Publications
- Open Access
- 11 March 2026
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (4) , 664-669
The impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France
- 11 March 2026
- Published by Elsevier in Journal of Cystic Fibrosis
- Vol. 25 (4) , 664-669
Open AccessThe impact of progressive expansion of elexacaftor-tezacaftor-ivacaftor availability on lung transplant for cystic fibrosis in France
- 16 June 2025
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 88, 101186
Use of complementary medicines and self-medication practices in cystic fibrosis – MUCAUTOMED study
- 16 June 2025
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 88, 101186
Use of complementary medicines and self-medication practices in cystic fibrosis – MUCAUTOMED study
- Open Access
- 26 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 384 (6694) , eadf5489
Ciliopathy patient variants reveal organelle-specific functions for TUBB4B in axonemal microtubules
Tubulin, one of the most abundant cytoskeletal building blocks, has numerous isotypes in metazoans encoded by different conserved genes. Whether these distinct isotypes form cell type– and context-specific microtubule structures is poorly understood. Based on a cohort of 12 patients with primary ciliary dyskinesia as well as mouse mutants, we identified and characterized variants in the TUBB4B isotype that specifically perturbed centriole and cilium biogenesis. Distinct TUBB4B variants differentially affected microtubule dynamics and cilia formation in a dominant-negative manner. Structure-function studies revealed that different TUBB4B variants disrupted distinct tubulin interfaces, thereby enabling stratification of patients into three classes of ciliopathic diseases. These findings show that specific tubulin isotypes have distinct and nonredundant subcellular functions and establish a link between tubulinopathies and ciliopathies.
- 26 April 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 384 (6694) , eadf5489
Open AccessCiliopathy patient variants reveal organelle-specific functions for TUBB4B in axonemal microtubules
Tubulin, one of the most abundant cytoskeletal building blocks, has numerous isotypes in metazoans encoded by different conserved genes. Whether these distinct isotypes form cell type– and context-specific microtubule structures is poorly understood. Based on a cohort of 12 patients with primary ciliary dyskinesia as well as mouse mutants, we identified and characterized variants in the TUBB4B isotype that specifically perturbed centriole and cilium biogenesis. Distinct TUBB4B variants differentially affected microtubule dynamics and cilia formation in a dominant-negative manner. Structure-function studies revealed that different TUBB4B variants disrupted distinct tubulin interfaces, thereby enabling stratification of patients into three classes of ciliopathic diseases. These findings show that specific tubulin isotypes have distinct and nonredundant subcellular functions and establish a link between tubulinopathies and ciliopathies.
- Open Access
- 29 August 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (10)
EEF2-inactivating toxins engage the NLRP1 inflammasome and promote epithelial barrier disruption
Human airway and corneal epithelial cells, which are critically altered during chronic infections mediated by Pseudomonas aeruginosa, specifically express the inflammasome sensor NLRP1. Here, together with a companion study, we report that the NLRP1 inflammasome detects exotoxin A (EXOA), a ribotoxin released by P. aeruginosa type 2 secretion system (T2SS), during chronic infection. Mechanistically, EXOA-driven eukaryotic elongation factor 2 (EEF2) ribosylation and covalent inactivation promote ribotoxic stress and subsequent NLRP1 inflammasome activation, a process shared with other EEF2-inactivating toxins, diphtheria toxin and cholix toxin. Biochemically, irreversible EEF2 inactivation triggers ribosome stress–associated kinases ZAKα- and P38-dependent NLRP1 phosphorylation and subsequent proteasome-driven functional degradation. Finally, cystic fibrosis cells from patients exhibit exacerbated P38 activity and hypersensitivity to EXOA-induced ribotoxic stress–dependent NLRP1 inflammasome activation, a process inhibited by the use of ZAKα inhibitors. Altogether, our results show the importance of P. aeruginosa virulence factor EXOA at promoting NLRP1-dependent epithelial damage and identify ZAKα as a critical sensor of virulence-inactivated EEF2.
- 29 August 2023
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 220 (10)
Open AccessEEF2-inactivating toxins engage the NLRP1 inflammasome and promote epithelial barrier disruption
Human airway and corneal epithelial cells, which are critically altered during chronic infections mediated by Pseudomonas aeruginosa, specifically express the inflammasome sensor NLRP1. Here, together with a companion study, we report that the NLRP1 inflammasome detects exotoxin A (EXOA), a ribotoxin released by P. aeruginosa type 2 secretion system (T2SS), during chronic infection. Mechanistically, EXOA-driven eukaryotic elongation factor 2 (EEF2) ribosylation and covalent inactivation promote ribotoxic stress and subsequent NLRP1 inflammasome activation, a process shared with other EEF2-inactivating toxins, diphtheria toxin and cholix toxin. Biochemically, irreversible EEF2 inactivation triggers ribosome stress–associated kinases ZAKα- and P38-dependent NLRP1 phosphorylation and subsequent proteasome-driven functional degradation. Finally, cystic fibrosis cells from patients exhibit exacerbated P38 activity and hypersensitivity to EXOA-induced ribotoxic stress–dependent NLRP1 inflammasome activation, a process inhibited by the use of ZAKα inhibitors. Altogether, our results show the importance of P. aeruginosa virulence factor EXOA at promoting NLRP1-dependent epithelial damage and identify ZAKα as a critical sensor of virulence-inactivated EEF2.
- Open Access
- 1 May 2021
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 38 (5) , 466-476
Aspergillose bronchopulmonaire allergique (ABPA) et mucoviscidose : mécanismes, diagnostic et alternatives thérapeutiques
- 1 May 2021
- Published by Elsevier in Revue des Maladies Respiratoires
- Vol. 38 (5) , 466-476
Open AccessAspergillose bronchopulmonaire allergique (ABPA) et mucoviscidose : mécanismes, diagnostic et alternatives thérapeutiques
- 1 September 2016
- Published by European Respiratory Society (ERS)
- Vol. 48 (suppl 60) , OA273
Management of bronchiectasis in Europe: Data from the European bronchiectasis registry (EMBARC)
Introduction: There are no published data on the management of bronchiectasis across Europe. Methods: The European Bronchiectasis registry (EMBARC) is a prospective observational study of patients with HRCT confirmed bronchiectasis. Data on current treatments were evaluated in relation to severity of disease and bacterial infection. Results: 2031 patients were included from 23 European Countries. Mean age was 63 years and 58% were female. The most common aetiologies were idiopathic (39%) and post-infective (27%). Mean FEV1 was 71% predicted. 51.3% had 2 or more exacerbations/year and 20.5% of patients were infected with Pseudomonas aeruginosa . The most common treatment across the population was inhaled corticosteroids (ICS- 55%), usually in combination with long acting beta-agonists (56.4%). Inhaled antibiotics were used in 10.8% (predominantly colistin 65.9%). Long term (>28 days) oral antibiotics were used in 19.4% (azithromycin- 74.2%). Mucoactive drugs were infrequently used. There was a significantly higher use of long term antibiotics in more severe patients, assessed by the bronchiectasis severity index (p<0.0001) P. aeruginosa infection strongly influenced treatment patterns, with increased use of ICS (78.4%,p=0.005), inhaled antibiotics (40.4%,p<0.0001) and long term oral antibiotics (28.3%,p<0.0001). 12.3% were prescribed combined inhaled antibiotics and azithromycin. Only 10.4% using inhaled antibiotics did not have a history of P. aeruginosa infection. Conclusions: P. aeruginosa infection is the primary driver for long term antibiotic treatment. The EMBARC registry will provide a useful benchmark to evaluate the impact of the upcoming ERS guidelines on clinical practice.
- 1 September 2016
- Published by European Respiratory Society (ERS)
- Vol. 48 (suppl 60) , OA273
Management of bronchiectasis in Europe: Data from the European bronchiectasis registry (EMBARC)
Introduction: There are no published data on the management of bronchiectasis across Europe. Methods: The European Bronchiectasis registry (EMBARC) is a prospective observational study of patients with HRCT confirmed bronchiectasis. Data on current treatments were evaluated in relation to severity of disease and bacterial infection. Results: 2031 patients were included from 23 European Countries. Mean age was 63 years and 58% were female. The most common aetiologies were idiopathic (39%) and post-infective (27%). Mean FEV1 was 71% predicted. 51.3% had 2 or more exacerbations/year and 20.5% of patients were infected with Pseudomonas aeruginosa . The most common treatment across the population was inhaled corticosteroids (ICS- 55%), usually in combination with long acting beta-agonists (56.4%). Inhaled antibiotics were used in 10.8% (predominantly colistin 65.9%). Long term (>28 days) oral antibiotics were used in 19.4% (azithromycin- 74.2%). Mucoactive drugs were infrequently used. There was a significantly higher use of long term antibiotics in more severe patients, assessed by the bronchiectasis severity index (p<0.0001) P. aeruginosa infection strongly influenced treatment patterns, with increased use of ICS (78.4%,p=0.005), inhaled antibiotics (40.4%,p<0.0001) and long term oral antibiotics (28.3%,p<0.0001). 12.3% were prescribed combined inhaled antibiotics and azithromycin. Only 10.4% using inhaled antibiotics did not have a history of P. aeruginosa infection. Conclusions: P. aeruginosa infection is the primary driver for long term antibiotic treatment. The EMBARC registry will provide a useful benchmark to evaluate the impact of the upcoming ERS guidelines on clinical practice.